Loading...
•
Sep 30, 2020
Travere Q3 2020 Earnings Report
Retrophin reported strong execution across clinical, commercial, and business development disciplines.
Key Takeaways
Retrophin, Inc. reported a 15% increase in net product sales, reaching $51.1 million for the third quarter of 2020. The company is progressing with its clinical trials for sparsentan in FSGS and IgAN, and has an agreement to acquire OT-58 for classical homocystinuria treatment.
Patient enrollment nears completion in the Phase 3 DUPLEX Study for sparsentan in FSGS; topline results expected in Q1 2021.
The Phase 3 PROTECT Study of sparsentan in IgAN achieved enrollment of the 280th patient; topline data anticipated in Q3 2021.
Agreement announced to acquire OT-58 for the treatment of classical homocystinuria.
Net product sales for Q3 2020 were $51.1 million, a 15% increase compared to $44.4 million in Q3 2019.
Forward Guidance
Retrophin anticipates net product sales for the full year 2020 will exceed the previous guidance of mid-single-digit percentage growth compared to 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...